HAVCR2 and neoplasm: Preliminary studies have shown that simultaneously blocking TIGIT and either PD-1 or TIM3 promotes immune cell proliferation, cytokine release, and degranulation and reverses T-cell exhaustion, which in turn results in tumor rejection and protective memory responses 120,128.